European Commission grants marketing authorisation for Lilly’s Mounjaro® (tirzepatide), the first GIP and GLP-1 receptor agonist for adults with type 2 diabetes in Europe
Eli Lilly and Company announced today that the European Commission has granted marketing authorisation for the use of Mounjaro® (tirzepatide), a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist, as an adjunct to diet and exercise for the treatment of adults with insufficiently controlled type 2 diabetes mellitus. The decision follows the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use’s (CHMP) positive opinion issued in July 2022.
As the first GIP and GLP-1 receptor agonist approved by the European Commission, tirzepatide is a single molecule that activates the body’s receptors for GIP and GLP-1, which are natural incretin hormones responsible for regulating blood glucose levels in response to eating food.
The decision is based on data from the SURPASS phase 3 global clinical development program, which included placebo and active comparators of injectable semaglutide 1 mg, insulin glargine and insulin degludec. Efficacy was evaluated for tirzepatide5 mg, 10 mg and 15 mg used alone or in combination with commonly prescribed diabetes medications, including metformin, SGLT2 inhibitors, sulphonylureas and insulin glargine. Participants in the SURPASS program achieved average A1C reductions between 1.87% and 2.24% for tirzepatide5 mg, between 1.89% and 2.59% for tirzepatide10 mg and between 2.07% and 2.59% for tirzepatide15 mg.
The most frequently reported adverse reactions were gastrointestinal disorders, including nausea, diarrhoea and vomiting. In general, these reactions were mostly mild or moderate in severity and occurred more often during dose escalation and decreased over time.
Tirzepatide will be available in six doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg).
About Lilly
Lilly unites caring with discovery to create medicines that make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer’s disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.
Tags in this Article:
Related articles
Diabetes: the public health emergency hiding in plain sight
Diabetes is a serious and growing problem in Europe. Diabetes does not just affect people living with the condition; it costs the European economy €188 billion. Bold and urgent actions are needed as the disease is responsible for a public health crisis, one that is under recognised and not given the priority it needs.
The story of insulin: the world’s first life-saving diabetes drug
A century ago, researchers from the University of Toronto made a scientific breakthrough that transformed the treatment of diabetes forever: the discovery of insulin for the treatment of humans. What does the future hold?
A century of diabetes breakthroughs
Diabetes is a relentless condition to live with, but huge progress has been made.